Lungpacer Medical Inc. news
An average of 14,000 pulmonary, critical care and sleep medicine clinicians and researchers from around the world attend the ATS multidisciplinary conference each year. Unfortunately, due to the COVID-19 global crisis the 2020 meeting has been cancelled. However, Lungpacer Medical, Inc. is pleased to announce that four preclinical abstracts were accepted for poster presentation, and one for podium presentation, all of which will be published.<
Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace™ System, a next generation product, into the RESCUE 3 pivotal clinical study studying faster ventilator independence. Lungpacer is dedicated to natural breathing by developing minimally invasive technologies designed to help patients wean off mechanical ventilation and breathe on their own. The RESCUE 3 study is the third i
Greifswald University Hospital tests new method (Lungpacer® System) for weaning of respiratory patients Constanze Steinke Pressearbeit Universität Greifswald 07/10/2020 08:54 Department B for Internal Medicine of the University Medical Center Greifswald successfully used, within an international multi-center trial, a special diaphragmatic stimulation therapy to treat a COVID-19 patient as the first clinical site in Europe. “The first patient treated in this trial ha
Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today that the FDA has approved the Emergency Use Authorization for the use of the Lungpacer Diaphragm Pacing Therapy System (DPTS) to assist in weaning patients determined by their healthcare provider to be at high risk of weaning failure. According to the FDA letter, “patients at high risk of weaning failure include COVID-19 patients requiring ventila
An average of 14,000 pulmonary, critical care and sleep medicine clinicians and researchers from around the world attend the ATS multidisciplinary conference each year. Unfortunately, due to the COVID-19 global crisis the 2020 meeting has been cancelled. However, Lungpacer Medical, Inc. is pleased to announce that four preclinical abstracts were accepted for poster presentation, and one for podium presentation, all of which will be published. Lungpacer Medical, Inc. also had two a